AU784657B2 - Delivery of proteins across polar epithelial cell layers - Google Patents

Delivery of proteins across polar epithelial cell layers Download PDF

Info

Publication number
AU784657B2
AU784657B2 AU13392/01A AU1339201A AU784657B2 AU 784657 B2 AU784657 B2 AU 784657B2 AU 13392/01 A AU13392/01 A AU 13392/01A AU 1339201 A AU1339201 A AU 1339201A AU 784657 B2 AU784657 B2 AU 784657B2
Authority
AU
Australia
Prior art keywords
moiety
protein drug
domain
activity
bioactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU13392/01A
Other languages
English (en)
Other versions
AU1339201A (en
Inventor
Ann Daugherty
David J. Fitzgerald
Miriam Mckee
Randall J. Mrsny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
US Department of Health and Human Services
Original Assignee
Genentech Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, US Department of Health and Human Services filed Critical Genentech Inc
Publication of AU1339201A publication Critical patent/AU1339201A/en
Application granted granted Critical
Publication of AU784657B2 publication Critical patent/AU784657B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU13392/01A 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers Ceased AU784657B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
US60/160923 1999-10-22
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Publications (2)

Publication Number Publication Date
AU1339201A AU1339201A (en) 2001-05-08
AU784657B2 true AU784657B2 (en) 2006-05-18

Family

ID=22579051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13392/01A Ceased AU784657B2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Country Status (8)

Country Link
US (1) US7824695B1 (https=)
EP (1) EP1242122B1 (https=)
JP (2) JP2003512441A (https=)
AT (1) ATE444081T1 (https=)
AU (1) AU784657B2 (https=)
CA (1) CA2389302C (https=)
DE (1) DE60043070D1 (https=)
WO (1) WO2001030392A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1000163T3 (da) * 1997-07-11 2006-02-06 Us Gov Health & Human Serv Pseudomonas-exotoksin A-lignende kimære immunogener
DE60043070D1 (de) * 1999-10-22 2009-11-12 Genentech Inc Proteine-abgabe durch polare epithelzellen schichte
US20090285771A1 (en) 2004-10-04 2009-11-19 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
WO2007109110A2 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN121513216A (zh) 2018-03-08 2026-02-13 应用分子转运公司 用于经口递送的毒素衍生的递送构建体
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2000046246A1 (en) * 1999-02-02 2000-08-10 The General Hospital Corporation Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
AU7694594A (en) 1993-09-06 1995-03-27 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
ATE204300T1 (de) 1994-05-13 2001-09-15 Biovation Ltd Zielzellen-bindende chimäre peptide
JP2001504334A (ja) * 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
DK1000163T3 (da) * 1997-07-11 2006-02-06 Us Gov Health & Human Serv Pseudomonas-exotoksin A-lignende kimære immunogener
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
DE60043070D1 (de) * 1999-10-22 2009-11-12 Genentech Inc Proteine-abgabe durch polare epithelzellen schichte
WO2001031020A1 (en) * 1999-10-22 2001-05-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Disulfide conjugated cell toxins and methods of making and using them
DE60137969D1 (de) 2000-12-21 2009-04-23 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2000046246A1 (en) * 1999-02-02 2000-08-10 The General Hospital Corporation Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUB MED ABSTRACT 8562904 *

Also Published As

Publication number Publication date
WO2001030392A3 (en) 2002-07-11
AU1339201A (en) 2001-05-08
CA2389302C (en) 2011-03-15
DE60043070D1 (de) 2009-11-12
EP1242122B1 (en) 2009-09-30
JP2003512441A (ja) 2003-04-02
CA2389302A1 (en) 2001-05-03
US7824695B1 (en) 2010-11-02
WO2001030392A2 (en) 2001-05-03
ATE444081T1 (de) 2009-10-15
EP1242122A2 (en) 2002-09-25
JP2012051939A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
US6296843B1 (en) Mutagenized IL 13-based chimeric molecules
JP2012051939A (ja) 極性上皮細胞層を横断するタンパク質の送達
US6423513B1 (en) Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins
EP1007696B1 (en) Il-13 receptor specific chimeric proteins and uses thereof
US7713737B2 (en) Methods and compositions for needleless delivery of macromolecules
US6251866B1 (en) Conjugates targeted to the interleukin-2 receptor
US20090148401A1 (en) Methods and compositions for needleless delivery of binding partners
JP2010500359A (ja) 針を使わない粒子の送達のための方法及び組成物
JP2004507264A (ja) インターロイキン１３のアミノ酸置換変異体
US6846484B2 (en) DTAT fusion toxin
Nash et al. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins
US20090305978A1 (en) Methods for increasing the size of animals using needleless delivery constructs
US20020119120A1 (en) Amino acid substitution mutants of interleukin 13
JP2006516253A (ja) 自己免疫疾患を治療および／または予防する方法
CN101072584A (zh) 用于无针输送大分子的方法和组合物